Drugs / IL13Rα2 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06355908 | Mar 2024 → May 2026 | glioma | Yang Zhang | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL13Rα2 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06355908 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cell therapy” NCT06355908 ↗ |
| Route | Other | “administered via intraventricular infusion” NCT06355908 ↗ |
| Target | IL13RA2 | “IL13Ra2-targeted CAR-T cells” NCT06355908 ↗ |